Bionomics Investor Presentation Deck
BNC210 Phase 2b PTSD ATTUNE Study Underway
WEEK 1
Phase 2b
1:1 RANDOMIZED
DOUBLE-BLIND
PLACEBO-CONTROLLED
BNC210 MONOTHERAPY
IN PTSD PATIENTS
-200 Subjects
Bionomics
2 3
4
5
OUTPATIENT BID DOSING
6 7
BNC 210 900 mg oral tablet
PLACEBO
SECONDARY ENDPOINTS
9
Various patient-reported symptoms
of PTSD, changes in anxiety and
depression symptoms, and global
and social functioning;
Safety & tolerability endpoints
10
11 12
FOLLOW-UP
PRIMARY ENDPOINT
Investigator-rated PTSD symptoms
on CAPS-5 Total Symptom Severity
Scores in change from Baseline to
Week 12 compared to placebo
Fast Track designation from FDA
BID = Twice daily dosing
CAPS-5 = Clinician-Administered PTSD Scale for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5)
15
欧
ATTUNE Study 19
PHASE 2b
Single potential registrational-
supporting trial for monotherapy
treatment in PTSD
KEY INCLUSION CRITERIA
Female and male (18-75 years)
Current PTSD diagnosis
CAPS-5≥ 30 (Screening & Baseline)
(& ≤ 25% decrease Screening to Baseline)
~25 Sites
Topline data expected 1H'23View entire presentation